Stem cell

MitoSense Inc. and Uppsala University, in Collaboration with Elliott Mitochondrial Center and Sallie Astor Burdine Breast Foundation, Announce Breakthrough in Mitochondrial Preservation

Retrieved on: 
Thursday, January 25, 2024
Research, Stem cell, ALS, Health, Collaboration, Biotechnology, Partnership, Mitochondrion, Seminal vesicles, Injury, Alzheimer's disease, Uppsala University, Parkinson's disease, Pharmaceutical industry

This method, utilizing extracellular vesicles from mesenchymal stromal cells (imEVs), marks a significant advancement in mitochondrial medicine.

Key Points: 
  • This method, utilizing extracellular vesicles from mesenchymal stromal cells (imEVs), marks a significant advancement in mitochondrial medicine.
  • Karl-Henrik Grinnemo and Sergey Rodin of Uppsala University, vital contributors to this research, described the study as a "milestone in mitochondrial science."
  • "The partnership with Elliott Mitochondrial Center and the Sallie Astor Burdine Breast Foundation has been instrumental in this discovery, reflecting our collective commitment to pioneering medical solutions," he stated.
  • This collaborative effort represents a major addition to MitoSense Inc.'s achievements, highlighting the company's crucial role in advancing medical science and enhancing patient care.

MitoSense Inc. and Uppsala University, in Collaboration with Elliott Mitochondrial Center and Sallie Astor Burdine Breast Foundation, Announce Breakthrough in Mitochondrial Preservation

Retrieved on: 
Thursday, January 25, 2024
Research, Stem cell, ALS, Health, Collaboration, Biotechnology, Partnership, Mitochondrion, Seminal vesicles, Injury, Alzheimer's disease, Uppsala University, Parkinson's disease, Pharmaceutical industry

This method, utilizing extracellular vesicles from mesenchymal stromal cells (imEVs), marks a significant advancement in mitochondrial medicine.

Key Points: 
  • This method, utilizing extracellular vesicles from mesenchymal stromal cells (imEVs), marks a significant advancement in mitochondrial medicine.
  • Karl-Henrik Grinnemo and Sergey Rodin of Uppsala University, vital contributors to this research, described the study as a "milestone in mitochondrial science."
  • "The partnership with Elliott Mitochondrial Center and the Sallie Astor Burdine Breast Foundation has been instrumental in this discovery, reflecting our collective commitment to pioneering medical solutions," he stated.
  • This collaborative effort represents a major addition to MitoSense Inc.'s achievements, highlighting the company's crucial role in advancing medical science and enhancing patient care.

Cell Cryopreservation Market Research Report 2024 - ResearchAndMarkets.com

Retrieved on: 
Friday, January 12, 2024
Biotechnology, Health, Medical Devices, Conditional sentence, Cryopreservation, Regenerative medicine, Cell, Research, Infertility, B cell, IVF, Risk, Tissue engineering, COVID-19, Sigma-Aldrich, Biobank, Stem cell, Prevalence

The "Cell Cryopreservation Market Size, Share & Trends Analysis Report By Product (Cell Freezing Media, Equipment), By Application (Stem Cells, Sperm Cells), By End-use (Biobanks, IVF), By Region, And Segment Forecasts, 2024 - 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Cell Cryopreservation Market Size, Share & Trends Analysis Report By Product (Cell Freezing Media, Equipment), By Application (Stem Cells, Sperm Cells), By End-use (Biobanks, IVF), By Region, And Segment Forecasts, 2024 - 2030" report has been added to ResearchAndMarkets.com's offering.
  • The increased demand for cost-effective cryopreservation medium has stemmed from increased research & development (R&D) activities to create advanced medicines.
  • For example, Merck KGaA's Sigma Aldrich brand provides frozen media solutions for stem cell applications while ensuring optimal recovery and cell survival, thus, propelling the cryopreservation market growth.
  • Additionally, developments in freezing media formulation and cryopreservation techniques, as well as leveraging cryopreservation freezing media applications in fields such as tissue engineering, cellular treatment, and stem cell research, have driven the market at a substantial rate.

Gallant Therapeutics Raises Over $15 Million in Series A Funding to Advance Pipeline of "Off-the-Shelf" Stem Cell Therapies for Pets

Retrieved on: 
Monday, January 8, 2024
Pet, Cat, FDA, Conditional sentence, Health, Disease, Microsoft Exchange Server, SAN, Therapy, Dog, Chronic kidney disease, DVM, FCGS, Stem cell, OA, Veterinary medicine, Growth, Gallant, CKD, Pharmaceutical industry

SAN DIEGO, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Gallant Therapeutics , an animal health biotechnology company pioneering off-the-shelf stem cell therapies for pets, today announced the successful completion of its Series A financing, securing over $15 million.

Key Points: 
  • SAN DIEGO, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Gallant Therapeutics , an animal health biotechnology company pioneering off-the-shelf stem cell therapies for pets, today announced the successful completion of its Series A financing, securing over $15 million.
  • The successful funding round will enable Gallant to accelerate the development of its pipeline of potentially first-in-class allogeneic stem cell therapeutics, focusing on achieving conditional FDA approval for its leading therapeutic candidate targeting FCGS, a deadly disease with a high unmet medical need.
  • “We have made unprecedented progress this past year, hitting significant clinical, regulatory, and manufacturing milestones,” said Linda Black, DVM, Ph.D., CEO of Gallant Therapeutics.
  • This series A funding represents a crucial step toward Gallant’s vision of bringing "off-the-shelf" stem cell therapies to veterinary clinics worldwide.

Pluri Launches Advanced Global Cell Therapy Contract Development and Manufacturing Organization

Retrieved on: 
Monday, January 8, 2024
FDA, Cell, B cell, South Korea, PLUR, EVS, Stem cell, CDMO, Microsoft Exchange Server, Seminal vesicles, GMP, Knowledge, European Medicines Agency, Ministry, Exosome, Patient, Therapy, Automation, Fine chemical

Pluri, an established global leader in the development and manufacturing of cell-based therapeutics, launches new revenue-generating Contract Development and Manufacturing Organization (CDMO) division.

Key Points: 
  • Pluri, an established global leader in the development and manufacturing of cell-based therapeutics, launches new revenue-generating Contract Development and Manufacturing Organization (CDMO) division.
  • PluriCDMO™ will help innovative companies develop and manufacture life-changing therapies within the rapidly growing $5.2 billion cell and gene therapy sector.
  • HAIFA, Israel, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq: PLUR) (TASE: PLUR) (“Pluri” or the “Company”), a leading biotech company that transforms cells into solutions that promote global wellbeing and sustainability, today announced it has launched a new business division offering cell therapy manufacturing services as a Contract Development and Manufacturing Organization (CDMO): PluriCDMO™.
  • Its state-of-the-art 47 thousand square foot Good Manufacturing Practice (GMP) cell therapy production facility is expected to help customers and partners address key challenges in the development and manufacturing of cell-based therapies.

CRISPR Therapeutics Highlights Strategic Priorities and 2024 Outlook

Retrieved on: 
Monday, January 8, 2024
LNP, Liver, Gene editing, Risk, Autoimmunity, Moyamoya disease, FDA, CRSP, SLE, Lupus, Stem cell, ANGPTL3, Pharmacology, CHMP, Kingdom, Guide, CRISPR Therapeutics, Vertex, PDUFA, Human, Pharmacokinetics, RNA, EMA, CRISPR, Therapy, Genetics, Vertex Pharmaceuticals, Bill, Patient, CD70, SCD, T1D, Sickle cell disease, Partnership, Hypertriglyceridemia, Research, Insulin, Diabetes, Hospital, Clinical trial, GMP, European Medicines Agency, Growth, Committee, CD19, TDT, Cardiovascular disease, Good, ADC, Pharmaceutical industry

ZUG, Switzerland and BOSTON, Jan. 08, 2024 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today highlighted its strategic priorities and 2024 outlook as the Company enters its next phase of growth.

Key Points: 
  • ZUG, Switzerland and BOSTON, Jan. 08, 2024 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today highlighted its strategic priorities and 2024 outlook as the Company enters its next phase of growth.
  • Exa-cel is the first therapy to emerge from a strategic partnership between CRISPR Therapeutics and Vertex Pharmaceuticals.
  • Vertex leads global development, manufacturing, regulatory and commercialization of CASGEVY with support from CRISPR Therapeutics.
  • CRISPR Therapeutics continues to focus on resource efficiency and return on invested capital as it advances multiple clinical programs across its pipeline.

Beam Therapeutics Highlights Progress Across Base Editing Portfolio and Outlines 2024 Anticipated Milestones

Retrieved on: 
Monday, January 8, 2024
SCD, LNP, Liver, Beam Therapeutics, Pfizer, Conference, Genotype, Sickle cell disease, Gene editing, Second wave, Survival, ESCAPE, Biotechnology, IND, Research, AAT, Pizzicato, Mortality, G6PC, Therapy, Third wave, Clinical trial, Glucose, DSM-IV codes, GMP, Trial of the century, AATD, Transplant, Growth, Investment, Hematology, Stem cell, HBF, Safety, Liver disease, Piz, CTA, Genetic distance, Beam

CAMBRIDGE, Mass., Jan. 08, 2024 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today reported progress across the company’s hematology and genetic disease portfolios and provided updates on anticipated upcoming milestones.

Key Points: 
  • “Our vision is to establish Beam as a sustainable, fully integrated company pioneering a new class of genetic medicines with base editing.
  • Preclinical models suggest base editing could lead to improved HbF induction and lower residual disease-causing hemoglobin S compared to existing gene therapy options.
  • The company is on-track to report initial data on multiple patients from the BEACON trial in the second half of 2024.
  • Beam expects to report an initial clinical dataset for BEAM-201 in the second half of 2024.

Molecular Partners Provides Updates at 42nd Annual J.P. Morgan Healthcare Conference

Retrieved on: 
Sunday, January 7, 2024
NAMD, Conference, Gene family, Partnership, Neoplasm, Tumor microenvironment, IND, Hematopoietic stem cell transplantation, Radionuclide, CD47, Data, Myelodysplastic syndrome, Macrophage, Molecular Partners, HSC, Society, CHF, Novartis, ASH, COVID-19, DARPin, Toxicity, RDT, CD16, Stem cell, HSCT, Patient, Acute myeloid leukemia, Safety, Therapy, AML, DLL3, Health, SITC, Pharmaceutical industry

53 LR Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced it will present a business overview and provide its 2024 outlook at the 42nd Annual J.P. Morgan Healthcare Conference.

Key Points: 
  • 53 LR Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced it will present a business overview and provide its 2024 outlook at the 42nd Annual J.P. Morgan Healthcare Conference.
  • Data were presented at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition in December 2023.
  • Molecular Partners continues to progress its RDT platform and portfolio of projects, both in-house and in partnership with Novartis.
  • In addition to these updates, Novartis has returned the rights to the ensovibep program, previously under investigation for the treatment of COVID-19, to Molecular Partners.

Immorta Bio Announces Personalized Progenitor Cell Platform for Organ Specific Regeneration

Retrieved on: 
Tuesday, January 2, 2024
PPC, CSO, Cell, Patent, MIAMI, Treating, Tissue, Stem cell, Vaccine

MIAMI BEACH, Fla., Jan. 2, 2024 /PRNewswire/ -- Immorta Bio, Inc. announced today its Personalized Progenitor Cell (PPC) platform and filing of associated intellectual property. In addition to proprietary know-how and trade secrets, the company filed patent application #63/599440.

Key Points: 
  • MIAMI BEACH, Fla., Jan. 2, 2024 /PRNewswire/ -- Immorta Bio, Inc. announced today its Personalized Progenitor Cell (PPC) platform and filing of associated intellectual property.
  • "One of the limitations of commonly used stem cell therapies is their reliance on in vivo differentiation," said Thomas Ichim, President and CSO of Immorta Bio.
  • Those cells are then administered in quantities required to achieve organ rejuvenation, a state, Immorta Bio calls, Stem Cell Revivify™.
  • "Immorta Bio is focused on Treating Diseases of Aging and Treating Aging as Disease™," said Dr. Boris Reznik, Chairman and CEO of Immorta Bio.

The Largest Biotech City in Europe Will Soon Be Built, With an Investment Amounting to 7 Billion Euros

Retrieved on: 
Friday, November 17, 2023
3D bioprinting, Invention, Gene editing, Biotechnology, Antibody, Research, GDP, BIO, Viktorija, CDMO, Republic, Gene, GMP, Innovation, Growth, A-DNA, Global health, Employment, Stem cell, Economy, Nature, Life, Fine chemical

The total investment for this biotech campus is projected to reach approximately 7 billion euros over the next decade.

Key Points: 
  • The total investment for this biotech campus is projected to reach approximately 7 billion euros over the next decade.
  • Prof. Vladas Algirdas Bumelis, founder and CEO of Northway Biotech and Celltechna, key components of the Northway Group, highlighted Lithuania's strong global standing in biotechnology.
  • "We envision BIO CITY as a frontrunner in the European biotechnology, by uniquely integrating various biotech segments into a single, synergistic ecosystem.
  • The global biotechnology market, currently valued at over 1,130 billion euros, is anticipated to grow to be worth more than 2,775 billion euros by 2030.